Nitib 140mg Capsule 30’s

Nitib 140mg Capsule – Targeted Treatment for Blood Cancers

Nitib 140mg Capsule contains Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of various cancers, including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib works by targeting and inhibiting BTK, a protein essential for the survival and proliferation of cancerous B-cells, helping to control the growth of abnormal cells and improve overall treatment outcomes.

Uses:

• Chronic Lymphocytic Leukemia (CLL): Used for the treatment of CLL, including CLL with del(17p) or del(11q) chromosomal abnormalities.
• Mantle Cell Lymphoma (MCL): Treatment for MCL in patients who have received at least one prior therapy.
• Waldenström’s Macroglobulinemia (WM): Used for the treatment of WM in patients who are symptomatic.
• Other B-cell malignancies: May be used for other B-cell related cancers under medical supervision.

How Nitib 140mg Capsule Works:

Ibrutinib selectively inhibits Bruton’s tyrosine kinase (BTK), a crucial enzyme involved in B-cell receptor signaling. By blocking BTK, Nitib prevents the survival and proliferation of B-cells that contribute to various blood cancers. This targeted action helps to slow or stop the growth of cancer cells, leading to disease control and improved patient outcomes.

Common Side Effects:

• Diarrhea
• Fatigue
• Nausea
• Headache
• Bruising
• Infections

Serious Side Effects (Seek Immediate Medical Attention):

• Heart problems such as arrhythmia (irregular heartbeats)
• Severe bleeding or bruising
• Infections such as pneumonia or sepsis
• Liver issues including jaundice or liver dysfunction
• Kidney problems
• Severe allergic reactions, including rash, itching, or difficulty breathing

Key Features:

• Contains Ibrutinib, a targeted BTK inhibitor for blood cancers.
• Blocks BTK activity to prevent the survival of cancerous B-cells.
• Available as an oral capsule for easy daily administration.
• Approved for use in several types of blood cancers, including CLL, MCL, and WM.

Precautions:

• Bleeding Risk: Ibrutinib may increase the risk of bleeding. Patients should be monitored for signs of bleeding and bruising.
• Heart Monitoring: Due to the potential for arrhythmia, patients should be monitored for heart problems during treatment.
• Infections: Ibrutinib may make the immune system weaker, increasing the risk of infections.
• Pregnancy Warning: Nitib 140mg Capsule is not recommended during pregnancy. It can harm an unborn baby. Women of childbearing age should use effective contraception during treatment.

Frequently Asked Questions (FAQ):

1. What is Nitib 140mg Capsule used for?
   Nitib is used for the treatment of blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM).
2. How does Nitib 140mg Capsule work?
   Nitib works by inhibiting Bruton’s tyrosine kinase (BTK), which is essential for the survival of B-cells. This helps stop the uncontrolled growth of cancerous B-cells in blood cancers.
3. What should I do if I miss a dose of Nitib?
   If you miss a dose, take it as soon as you remember. If it’s almost time for the next dose, skip the missed dose—do not take two doses at once.
4. Is Nitib 140mg Capsule safe during pregnancy?
   Nitib is not recommended during pregnancy as it may harm the fetus. Women should avoid becoming pregnant during treatment and use effective contraception.

References:

1. Imbruvica (Ibrutinib) Drug Information
   Available from: https://www.imbruvica.com
   Accessed on: November 9, 2024.
2. European Medicines Agency (EMA) – Ibrutinib (Imbruvica) Summary of Product Characteristics
   Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica
   Accessed on: November 9, 2024.